- A +

Events › 2017

13Dec.2017

Guggenheim Securities 5th Annual Boston Healthcare Conference 2017, Boston, MA, USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present on Wednesday, December 13th, 2017, at The Intercontinental Boston Hotel and will host investor meetings.

14 - 15Nov.2017

The Stifel Nicolaus Weisel Healthcare Conference 2017, New York, NY, USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present on Wednesday, November 15th, 2017, at the Lotte New York Palace Hotel and will host investor meetings.

Live Webcast: http://wsw.com/webcast/stifel10/sight/

 

11 - 14Nov.2017

American Academy of Ophthalmology, New Orleans (LA)

Barrett Katz, MD, Chief Medical Officer, will attend the American Academy of Ophthalmology.

09Nov.2017

Ophthalmology Innovation Summit @ AAO, New Orleans (LA) 

Barrett Katz, MD, Chief Medical Officer, will present on November 9, 2017, 8:47 - 8:54 am CDT, in Company Showcase 1 at the Hyatt Regency Hotel on the occasion of the American Academy of Ophthalmology, November 11-14, 2017, in New Orleans (LA). Thomas Gidoin, Chief Financial Officer, will host investor meetings. 

17 - 20Oct.2017

ESGCT, Berlin, Germany

Five abstracts are accepted for one oral and four poster presentations at the 25th meeting of the European Society of Gene and Cell Therapy (ESGCT) concerning both of its lead products.

=> GS010 - Leber’s Hereditary Optic Neuropathy (LHON) 

78 week follow-up study results after intravitreal rAAV2/2-ND4 (GS010) injection in patients with vision loss due to G11778A ND4 Leber Hereditary Optic Neuropathy.

  • Poster Presentation ID P215
  • Wednesday 18th October 2017, 6:30 pm-9:00 pm

Humoral and cellular immune responses to AAV2 and ocular inflammation in patients after intravitreal injection of rAAV2/2-ND4 (GS010), an investigational gene therapy for the treatment of ND4 LHON

  • Poster Presentation ID P210
  • Thursday 19th October 2017, 6:45 pm-8:15 pm

=> GS030 – Optogenetics in Retinitis Pigmentosa (RP)

Efficacy and Safety of ocular AAV mediated optogenetic therapy for retinitis pigmentosa in rd1 mice and non-human primates support the First-in-Human clinical trial of GS030

  • Oral presentation OR07
  • Session S1b : Ocular and CNS Gene and Cell Therapy I
  • Wednesday 18 October 2017, 08:30 – 10:40 am  

Ocular tolerability of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) gene therapy product on blind rd1 mice injected intravitreously and exposed to 595 nm LED light

  • Poster Presentation ID P231
  • Wednesday 18th October 2017, 6:30 pm-9:00 pm

Toxicity, immunogenicity and biodistribution of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) gene therapy product after bilateral intravitreal administration in non-human primates

  • Poster Presentation ID P214
  • Thursday 19th October 2017, 6:45 pm-8:15 pm
10Oct.2017

Chardan Inaugural Gene Therapy Conference, NYC (US)

Thomas Gidoin, Chief Financial Officer, will present on October 10, 2017, at 1:00pm ET, at the Westin New York Grand Central Hotel, and host investor meetings.

27 - 28Sept.2017

5th Annual Targeting Ocular Diseases, Boston (MA), USA

Anne Douar, PhD, Project Director, is invited to give an oral presentation entitled " Optogenetic Therapy for Retinal Dystrophies " in Boston (MA).

  • Session:  Gene Editing & Gene Therapy Breakthroughs for Ouclar Disorders
  • Time & Place:  September 27, 5:30 PM
10 - 13Sept.2017

EUNOS, Budapest, Hungary

GenSight will present two posters on its lead gene therapy product GS010 to treat LHON. For both posters, details of the session are the followings :

Poster Session:  SESSION II. - AFFERENT VISUAL SYSTEM
Date & Time of the session: 12 September 2017, 12:30

  • GS010 - Phase I/II Clinical Trial Data after 78 Weeks of Follow-up

Scott Uretsky, MD, Neuro-Ophthalmology, Medical Director, will present " Phase I/II Safety and Visual Acuity Outcomes 78-weeks post-treatment with rAAV2/2-ND4, an investigational gene therapy for ND4 LHON ". (Poster Number: PA68).

  • GS010 - RESCUE and REVERSE Phase III Clinical Trials Baseline Characteristics

Patrick Yu-Wai-Man, MD, international coordinating investigator of the REVERSE study and Honorary Consultant in Ophthalmology at the Moorfields Eye Hospital in London, and the Newcastle Hospital, United Kingdom, will present " Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE  Phase III Clinical Gene Therapy Trials ". (Poster Number: PA81).

 

10Aug.2017

Ophthalmology Innovation Summit @ ASRS, Boston (MA) 

Mohamed Genead, MD, Chief Medical Officer, is invited to present the Topline results at Week 78 in Phase I/II Study of GS010 for the treatment of LHON at the OIS on the occasion of the Americal Society of Retina Specialists, August 11-15, 2017, in Boston (MA). 

  • Session:  Gene and Cell Therapy
  • Time:  2:45 - 3:20 PM
19 - 22Jun.2017

BIO International ConventionSan Diego, CA (US)

GenSight will attend and host partnering meetings. 

28 - 31May2017

ISCAS 2017 (IEEE International Symposium on Circuits And Systems), Baltimore, Maryland (US)

GenSight will give an oral presentation and a demonstration on its stimulation platform for optogenetic and bionic vision restoration.

  • Oral presentation:  A Stimulation Platform for Optogenetic and Bionic Vision Restoration (# 1678)

  Session: Integrated Biomedical Systems, BioMEMS & Biosensors/Actuators I

  Session code: B3L-J

  Time & Place: Tuesday May 30, 2017 from 13:30 - 15:00 in GB IX

  • Live Demonstration: a Stimulation Platform for Optogenetic and Bionic Vision Restoration (# 2524)

  Session: Demonstration Session I

  Session code: A4P-O

  Time & Place: Monday May 29, 2017 from 14:00 - 17:00 in HB Exhibits.

30May2017

15ème Forum Santé Gilbert Dupont, Hôtel Le Marois, Paris (France)

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer, will host investor meetings.

07 - 11May2017

2017 ARVO Annual Meeting, Baltimore, Maryland (US)

The company will present several posters on both its lead products and an oral presentation on its GS030 optogenetics product.

- GS010 aiming at treating LHON, a rare mitochondrial genetic disease

Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON.

Poster session:  Wednesday 10 May, 2017, 11.00am – 12.45pm, Session Low Vision Populations, Services and Treatments, Posterboard #: B0588, Abstract Number: 4681 - B0588

Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials. 

Poster session: Wednesday 10 May, 2017, 8.30am – 10.15am, Session Optic Neuropathy, Posterboard #: A0036, Abstract Number: 3865 - A0036

- GS030 based on optogenetics to treat RP

Long term visual restoration using optogenetic engineering of retinal ganglion cells with AAV2.7m8- ChrimsonR-tdTomato

Oral presentation:  Tuesday 9 May, 9.15-9.30 am, Session Diseases and Protection, Abstract Number # 1219

Visual acuity and optical flow in primate retinal ganglion cells treated with an optogenetic vision restoration strategy using ChrimsonR

Poster session:  Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0475 - Abstract Number: 5883 - B0475

Modeling the dynamics of light-driven microbial opsin ChrimsonR

Poster session:  Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0465 - Abstract Number: 5873 - B0465

04 - 05May2017

4th Annual Retinal Cell & Gene Therapy Innovation Summit, Baltimore (MD)

Pr. José-Alain Sahel, MD, Director of the Institut de la Vision (Sorbonne-Universités/Inserm/CNRS), Paris, Chairman of the Department of Ophthalmology at Centre Hospitalier National d'Ophtalmologie des XV-XX, Paris, Professor and Chairman of the Department of Ophthalmology at University of Pittsburgh School of Medicine and Medical Center, and co-founder of GenSight Biologics, will present Gene therapy for Leber hereditary optic neuropathy and neuroprotection of cone photoreceptors in rod-cone dystrophies”  on Friday, May 5, 2017, 11:10-11:30 am (local time) in Session 2 – Clinical Gene Therapy

03 - 04May2017

Deutsche Bank 42nd Annual Health Care Conference, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present on May 4, 2017, at 9:20am EST, at the InterContinental Boston Hotel and will host investor meetings.

22 - 28Apr.2017

American Academy of Neurology 69th Annual Meeting (AAN)

GenSight will give an oral presentation entitled "Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation" (Abstract number #2444) in Session S26: Neuro-ophthalmology/Neuro-Otology on April 25, 2017, at 4:18 PM (platform presentation number  005).

27Apr.2017

5th Annual ARM Cell&Gene Investor Day, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present at the ARM Cell&Gene Investor Day in Boston, MA, USA on Thursday, April 27, 2017, at 4:45 pm ET, The State Room, and will host investor meetings.

01 - 06Apr.2017

43rd NANOS Annual Meeting (North American Neuro-Ophthalmology Society)

GenSight gave an oral presentation and presented two posters on its lead product GS010 currently in Phase 3 in Europe and US aiming at treating LHON, a rare mitochondrial genetic disease

Both posters were presented at the session “Poster Session II: Scientific Advancements in Neuro-Ophthalmology” in the Category: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) on Tuesday, April 4, 2017 from 6:00 -9:30 pm, Room Location: Exhibit Hall C

Title:  Pediatric Leber Hereditary Optic Neuropathy (LHON): A Literature Review (Poster Number # 186)

Title:  Preliminary Baseline Characteristics of Patients with LHON Enrolled in RESCUE and REVERSE Gene Therapy Trials (Poster Number # 189)

Presentation took place on Tuesday, April 4th from 10:00am- 10:15am, in the Thurgood Marshall Ballroom

Title:  Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, Investigational Gene Therapy for ND4 LHON.

09 - 12Jan.2017

JP Morgan 35th Annual Healthcare Conference, San Francisco (CA), USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings. GenSight took this opportunity to meet with a numerous partners and companies. 

05 - 06Jan.2017

Oddo 20th Forum – Lyon, France

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings at the 20th Oddo Forum in Lyon, France on January 5-6, 2017